Characteristics of Real-World Patients with High-Risk BRAF(V600E/K)-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

PURPOSE: Real-world data from patients with BRAF(V600)-mutated, resected, stage III melanoma treated with dabrafenib plus trametinib as adjuvant targeted therapy are limited, and it is important to gain an understanding of the characteristics of this patient population, as well as of the patient jou...

Descripción completa

Detalles Bibliográficos
Autores principales: Quaglino, Pietro, Ascierto, Paolo A, Consoli, Francesca, Queirolo, Paola, Spagnolo, Francesco, Morelli, Maria Francesca, Berardi, Rossana, Chiarion-Sileni, Vanna, Tucci, Marco, Troiani, Teresa, Melotti, Barbara, Rossi, Ernesto, Mandala, Mario, Rinaldi, Gaetana, Marcon, Ilaria Gioia, Pizzuti, Matteo, Del Vecchio, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649847/
https://www.ncbi.nlm.nih.gov/pubmed/38027240
http://dx.doi.org/10.2147/CMAR.S423970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649847/
https://www.ncbi.nlm.nih.gov/pubmed/38027240
http://dx.doi.org/10.2147/CMAR.S423970

Ejemplares similares